10x Genomics Stock News

10x Genomics Inc (NASDAQ: TXG ) reported Q4 sales of $143.5 million , missing the consensus of $148.53 million. Sales increased 28% Y/Y, primarily due to increased consumables revenue driven by growth in cumulative instruments sold. The gross margin was 81% for the fourth quarter of 2021 compared to 83% a year ago. The decrease … Full story available on Benzinga.com

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2021 Results - Earnings Call Transcript

10x Genomics <> is trading ~18% lower in the post-market on Wednesday after the company set its 2022 revenue guidance below Wall Street forecasts despite a strong revenue beat for…

PLEASANTON, Calif., Feb. 16, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided outlook for 2022. Recent Highlights Revenue was $490.5 million for the full year and $143.5 million…

10x Genomics (NASDAQ:TXG) is scheduled to announce Q4 earnings results on Wednesday, February 16th, after market close.The consensus EPS Estimate is -$0.03 (+99.2% Y/Y) and the…

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

10x Genomics Inc - Class A (TXG) shares closed today 11.8% lower than it did at the end of yesterday. The stock is currently down 29.6% year-to-date, down 40.3% over the past 12 months, and up 98.7% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $135.47 and as low as $104.69 this week.Shares closed 49.8% below its 52-week high and 0.1% above its 52-week low.Trading volume this week was 0.7% higher than the 10-day average and 55.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 145.9% The company's stock price performance over the past 12 months lags the peer average by 149.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

10x Genomics Inc - Class A (TXG) shares closed today at 0.1% above its 52 week low of $104.69, giving the company a market cap of $9B. The stock is currently down 29.6% year-to-date, down 40.3% over the past 12 months, and up 98.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 55.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 145.9% The company's stock price performance over the past 12 months lags the peer average by 149.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

10x Genomics Inc - Class A (TXG) shares closed today at 1.5% above its 52 week low of $117.01, giving the company a market cap of $11B. The stock is currently down 18.1% year-to-date, down 27.2% over the past 12 months, and up 131.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 116.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 81.4% The company's stock price performance over the past 12 months lags the peer average by 118.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PUNE, India, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Global Next Generation Sequencing (NGS) Market is growing with a CAGR of 17.1% in the forecast period of 2022 to 2029 and is expected to reach USD 29,307.13 Million by 2029. The most appropriate, exclusive, realistic, and admirable Next Generation Sequencing (NGS) Market Research Report is delivered with devotion depending upon the business needs. With the precise base year and the historic year, estimations and calculations are performed in this industry report. Market share analysis and key trend analysis are the key accomplishing factors in this market report. Report helps to recognize how the market is going to perform in the forecast years by giving information about market definition, classifications, applications, and engagements. DBMR team provides Next Generation Sequencing (NGS) Market research report with loyalty that is promising and the way in which expected. Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-next-generation-sequencing-ngs-market Key Companies operating in the Next Generation Sequencing (NGS) Market are: Agilent Technologies Inc Thermo Fisher Scientific Inc QIAGEN Illumina Inc Bio-Rad Laboratories Inc Roche Sequencing (A subsidiary of F.

10x Genomics <> turned lower in afternoon trading after the companys management highlighted COVID-19 impact and supply chain issues.At the ongoing 40th Annual J.P

10x Genomics Inc - Class A (TXG) shares closed today at 1.7% above its 52 week low of $125.60, giving the company a market cap of $11B. The stock is currently down 14.2% year-to-date, down 19.8% over the past 12 months, and up 142.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 22.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 11.9% The company's stock price performance over the past 12 months lags the peer average by 47.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PLEASANTON, Calif., Dec. 22, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the company will be participating in the upcoming 40th Annual J.P.

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.